No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

Autophagy is the process by which cells digest and renew their internal structures, recycling damaged or malfunctioning ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

The innovation, he says, could transform the way scientists measure and address genomic breaks in gene-editing systems.

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Africa is grappling with severe food insecurity in the wake of consecutive droughts, climate change, and ongoing conflicts, which are affecting millions across the continent.

Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...